Also in a panel of multiple myeloma (Shi et al., 2002), glioblastoma, and prostate cancer cell lines (Neshat et al., 2001), PTEN deficiency was reported to be associated with enhanced sensitivity to the allosteric mTOR inhibitor Temsirolimus (CCI-779). This evidence concerns the gene PTEN and prostate cancer.